21791546

Source:http://linkedlifedata.com/resource/pubmed/id/21791546

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003873, umls-concept:C0030705, umls-concept:C0031437, umls-concept:C0039198, umls-concept:C0237753, umls-concept:C0392760, umls-concept:C0717758, umls-concept:C1122087, umls-concept:C1332714
pubmed:issue	10
pubmed:dateCreated	2011-9-21
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00234234
pubmed:abstractText	To analyse the therapeutic effects of etanercept (ETA) or adalimumab (ADA) on the numbers and phenotypes of CD4+CD25hi Tregs in RA patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100883501
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/IL2RA protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2 Receptor alpha Subunit, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor, http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein, http://linkedlifedata.com/resource/pubmed/chemical/adalimumab
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1462-0332
pubmed:author	pubmed-author:BeutheuStéphanieS, pubmed-author:BlacheCélineC, pubmed-author:BoyerOlivierO, pubmed-author:DedreuxIngridI, pubmed-author:JacquotSergeS, pubmed-author:Le LoëtXavierX, pubmed-author:LequerréThierryT, pubmed-author:RoucheuxArnaudA, pubmed-author:VittecoqOlivierO
pubmed:issnType	Electronic
pubmed:volume	50
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1814-22
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:21791546-Adult, pubmed-meshheading:21791546-Aged, pubmed-meshheading:21791546-Antibodies, Monoclonal, pubmed-meshheading:21791546-Antibodies, Monoclonal, Humanized, pubmed-meshheading:21791546-Antirheumatic Agents, pubmed-meshheading:21791546-Arthritis, Rheumatoid, pubmed-meshheading:21791546-Cell Count, pubmed-meshheading:21791546-Female, pubmed-meshheading:21791546-Health Status, pubmed-meshheading:21791546-Humans, pubmed-meshheading:21791546-Immunoglobulin G, pubmed-meshheading:21791546-Injections, Subcutaneous, pubmed-meshheading:21791546-Interleukin-2 Receptor alpha Subunit, pubmed-meshheading:21791546-Male, pubmed-meshheading:21791546-Middle Aged, pubmed-meshheading:21791546-Phenotype, pubmed-meshheading:21791546-Receptors, Tumor Necrosis Factor, pubmed-meshheading:21791546-Severity of Illness Index, pubmed-meshheading:21791546-T-Lymphocyte Subsets, pubmed-meshheading:21791546-T-Lymphocytes, Regulatory, pubmed-meshheading:21791546-Young Adult
pubmed:year	2011
pubmed:articleTitle	Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.
pubmed:affiliation	Inserm, U905, Institut Fédératif de Recherche Multidisciplinaire surles Peptides 23, Institute for Biomedical Research, University of Rouen, Faculté de Médecine-Pharmacie, Rouen, France.
pubmed:publicationType	Journal Article, Clinical Trial